Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10695323 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(12 years from now) | |
US10342780 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(12 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10464905 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(12 years from now) | |
US10918622 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-424) | Jan 27, 2030 |
New Chemical Entity Exclusivity(NCE) | Jan 27, 2028 |
Orphan Drug Exclusivity(ODE-451) | Dec 01, 2030 |
Drugs and Companies using PIRTOBRUTINIB ingredient
NCE-1 date: 27 January, 2027
Market Authorisation Date: 27 January, 2023
Treatment: Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (cll/sll) who have received at least two prior lines of therapy, including a btk inhibitor and a bcl-2 inhibitor
Dosage: TABLET;ORAL